Pharmacology of alfentanil and remifentanil
Upcoming SlideShare
Loading in...5
×
 

Pharmacology of alfentanil and remifentanil

on

  • 2,209 views

 

Statistics

Views

Total Views
2,209
Views on SlideShare
2,209
Embed Views
0

Actions

Likes
0
Downloads
22
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Pharmacology of alfentanil and remifentanil Pharmacology of alfentanil and remifentanil Presentation Transcript

  • SPEAKER:DR SHRIRANGMODERATOR:DR CHANDRAPPA
  • 1)Naturally Occurring: Morphine,Codeine,Papaverine,Thebaine2)Semisynthetic Heroin Dihydromorphone/morphinone Thebaine derivatives (e.g.,etorphine,buprenorphine)3)Synthetic A)Morphinan series (e.g., levorphanol,butorphanol) B)Diphenylpropylamineseries(e.g.,methadone) C)Benzomorphan series(e.g.pentazocine) D)Phenylpiperidine series (e.g., meperidine, fentanyl, sufentanil, alfentanil, remi fentanil)
  •  Alfentanil is synthetic opioid Phenylpiperidine series-Tetrazole derivative of fentanyl Introduced in 1980. Less potent(1/5th to 1/10th ) and Has 1/3rd the duration of action of fentanyl. It is Agonist at µ-receptor. View slide
  • µ-receptors actions: ANALGESIA: RESPIRATORY-Respiratory depression. GASTROINTESTINAL ↓ Gastric secretion ↓GI transit supraspinal and peripheral antidiarrheal ENDOCRINE: Skeletal muscle rigidity,prolactin release. OTHER: Pruritus Urinary retention (and/or δ) Biliary spasm (probably >1 receptor type) Cardiovascular effects(µ2) View slide
  • PHARMACODYNAMICS Central nervous system: Generalized slowing of the EEG. Intense muscle rigidity accompanied by loss of consciousness. No significant changes in ICP. Increases CSF pressure in patient with brain tumour(Jung R et al;Anaesth Analog 1990).
  •  RESPIRATORY SYSTEM Decreases respiratory rate,Tidal volume and increases airway resistance Ventilatory response to CO2 is decreased by 50% of the baseline value. Higher doses may produce apnea and a longer duration of respiratory depression.
  • CARDIOVASCULAR SYSTEM: Blunt cardiovascular and catecholamine responses to laryngoscopy and intubation. MAP,SVR and Pulmonary capillary wedge pressure are unaffected. Bradycardia and hypotension occurs when combined with propofol(1mg/kg).
  • GASTROINTESTINAL SYSTEM Nausea and vomting. Decreases GI motility and secretions. Increases common bile duct pressure-spasm of Sphincter of Oddi.
  • PHARMACOKINETICS Less lipid soluble, weaker base than other opioid pKa 6.8(others>7.4) results in 90% unbound plasma alfenatanil being non ionized at 7.4. Distribution:85-92% protein bound,volume of distribution(0.4-1 L/kg)smaller than fentanyl(3-8L/kg).
  •  Distribution half life:1 to 3.5 minutes. Elimination half life:84 to 90 minutes. Context-sensitive half life(time necessary for the plasma concentration to decrease 50% after discontinuation of the infusion):after 4 hours of infusion is 60 mins.
  • DOSAGE AND USES: Premedication: Dose: 250-500mcg. Induction with hypnotic: Dose:25-50mcg/kg IV
  •  Maintenance of anaesthesia: Intermittent bolus dose:- 5-10mcg/kg. Infusion:- 0.5-2mcg/kg/min.Total dose: Dependent on duration of procedure
  •  MONITORED ANESTHESIA CARE (MAC) (For sedated and responsive,spontaneously breathing patients). Induction of MAC: 3-8 mcg/kg Maintenance of MAC: 0.25 to 1 mcg/kg/min Total dose: 3-40 mcg/kg.
  •  Anilidopiperidine derivative. Introduced in 1991. Analgesic potency similar to fentanyl. (20-30 times more potent than alfentanil) Ultra short acting
  •  PHARMACODYNAMICS CNS: Concentration dependent slowing of EEG. Muscle rigidity-bolus doses. No effect on ICP. Preserves cerebral autoregulation. Less suppression of MEP compared to other opioids. Dose dependent decrease in CPP. No seizure activity.
  • CARDIOVASCULAR SYSTEM: Dose dependent decrease in MAP. Dose dependent hypotension and bradycardia
  •  RESPIRATORY SYSTEM: Dose dependent respiratory depression. Ventilatory response to CO2 is decreases by 50% of the baseline value. Recovery from remifentanil-induced respiratory depression is rapid-minute ventilation returns to baseline by 5-10 mins after the infusion s stopped.
  • GASTROINTESTINAL SYSTEM: Nausea(44%) and vomiting(21%). Delays gastric emptying and biliary drainage
  •  PHARMACOKINETICS: Smaller volume of distribution Vd-100ml/kg. Rapid clearance-40ml/min/kg. Metabolised by non specific plasma and tissue esterases to inactive metabolites. Clearance is not affected by Cholinesterase deficiency or anticholinergics.
  •  Distribution half life:1 minute Elimination half life:3-10 minutes. Context-sensitive half life:4 minutes-independent of the duration of infusion.
  • DOSAGE AND USES:1)Induction: Dose:0.5-1mcg/kg IV over 60 to 90 seconds.2)Maintenance of anaesthesia: -N2O(66%)+Isoflurane(0.4-1.5MAC) Dose:0.05-0.2mcg/kg/min. -Propofol(100-200mcg/kg/min) Dose:- 0.05-0.2mcg/kg/min
  • 3)Maintenance of anaesthesia in pediatric patients: -Birth to 2mnths of age N2o(70%):- 0.4-1mcg/kg/min. -1 to 12 yrs of age halothane/sevoflurane/isoflurane dose:-0.05-1.3mcg/kg/min.
  •  4) Monitored Anesthesia Care: -Single dose: 0.5-1mcg/kg over 30 to 60 seconds,give 90 seconds before the local anaesthetics. -Conti.infusion:Begining 5mins before local anaesthetics 0.1mcg/kg/min. after local anaesthetics 0.05mcg/kg/min.
  •  REFERENCES:1)Clinical Anesthesia 6th edn,Paul G.Barash.2)Pharmacology and Physiology in Anesthetic Practice 4th edn,Robert K. Stoelting.3)Miller’s Anesthesia 7th edn.4)Internet references.
  • THANK YOU